Thiophene analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

Antiviral compounds

ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R1, R 2 , R 2 ′, R 3 , R 3 ′, R 4 , R 4 ′, R 5′ , R 5′ m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Naphthyridine derivatives and their analogues inhibiting cytomegalovirus

Thiophene analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

Thiophene analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

Thiophene integrin inhibitors

The present invention comprises compounds that are effective inhibitors of integrins, particularly alphavbeta3 and alphavbeta5 integrins. Particularly, the compounds are of formula Iand pharmaceutically acceptable salts thereof wherein X,Y1 W, R1 to R5, A and B are defined according to the disclosure herein.

THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I: 120.-. (canceled)21. A compound selected from:5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHOXY-CYCLOHEXYL)-(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(CIS-4-[1,2,4]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(TRANS-4-[1,2,4]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(CIS-4-HYDROXY-CYCLOHEXYL)-(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(1-METHYL-PIPERIDIN-4-YL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID; HYDROCHLORIDE;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(4-CIS-[1,2,3]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(TRANS-4-[1,2,3]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;5-(3,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-FLUORO-CYCLOHEXYL)-(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID;and pharmaceutically acceptable salts thereof.2233.-. (canceled)34. A compound of claim 21 , wherein the compound is 5-(3 claim 21 ,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHOXY-CYCLOHEXYL)-(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID.35. A compound of claim 21 , wherein the compound is 5-(3 claim 21 ,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(CIS-4-[1 claim 21 ,2 claim 21 ,4]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID.36. A compound of claim 21 , wherein the compound is 5-(3 claim 21 ,3-DIMETHYL-BUT-1-YNYL)-3-[(TRANS-4-METHYL-CYCLOHEXANECARBONYL)-(TRANS-4-[1 claim 21 ,2 claim 21 ,4]TRIAZOL-1-YL-CYCLOHEXYL)-AMINO]-THIOPHENE-2-CARBOXYLIC ACID.37. A compound of claim 21 , wherein the compound is 5-(3 claim 21 ,3-DIMETHYL-BUT-1-YNYL)-3-[(CIS ...

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I: 2. (canceled)4. The compound according to claim 1 , wherein each A is independently cyclopropyl claim 1 , cyclohexyl claim 1 , pyrrolidinyl claim 1 , pyrazolidinyl claim 1 , imidazolidinyl claim 1 , piperazinyl claim 1 , piperadinyl claim 1 , phenyl claim 1 , naphthalenyl claim 1 , thienyl claim 1 , furanyl claim 1 , pyrrolyl claim 1 , pyrazolyl claim 1 , imidazolyl claim 1 , thiazolyl claim 1 , thiadiazolyl claim 1 , oxazolyl claim 1 , oxadiazolyl claim 1 , pyridyl claim 1 , pyrimidyl claim 1 , pyrazinyl claim 1 , pyridazinyl claim 1 , indolyl claim 1 , indazolyl claim 1 , benzimidazolyl claim 1 , benzoxazolyl claim 1 , benzodioxolyl claim 1 , benzothiazolyl claim 1 , benzothiadiazolyl claim 1 , benzothiophenyl claim 1 , dihydrobenzodioxinyl claim 1 , thienofuranyl claim 1 , thienothienyl claim 1 , thienopyrrolyl claim 1 , quinolinyl claim 1 , quinoxalinyl claim 1 , quinazolinyl claim 1 , cinnolinyl claim 1 , or triazolyl; and wherein each A is independently substituted with (R).57.-. (canceled)8. The compound according to claim 4 , wherein each A is independently piperazinyl claim 4 , piperadinyl claim 4 , thienyl claim 4 , furanyl claim 4 , pyrrolyl claim 4 , pyrazolyl claim 4 , imidazolyl claim 4 , thiazolyl claim 4 , oxazolyl claim 4 , thiadiazolyl claim 4 , pyrrolidinyl claim 4 , pyridyl claim 4 , pyrimidinyl claim 4 , pyrazinyl claim 4 , pyridazinyl claim 4 , benzoxazolyl claim 4 , benzodioxolyl claim 4 , benzothiazolyl claim 4 , benzothiadiazolyl claim 4 , benzothiophenyl claim 4 , dihydrobenzodioxinyl claim 4 , thienofuranyl claim 4 , thienothienyl claim 4 , quinolinyl claim 4 , or triazolyl claim 4 , each of which is substituted with (R).910.-. (canceled)11. The compound according to claim 1 , wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (R).12. The compound according to ...

Benzimidazole analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B′, X, Y, R 1 , R 1 ′, R 2 , R 2 ′, R 3 , R 3 ′, R 5 , R 5 ′, R 6 , m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I: 1. (canceled)3. (canceled)4. The compound according to claim 2 , wherein each A is independently cyclopropyl claim 2 , cyclohexyl claim 2 , pyrrolidinyl claim 2 , pyrazolidinyl claim 2 , imidazolidinyl claim 2 , piperazinyl claim 2 , piperadinyl claim 2 , phenyl claim 2 , naphthalenyl claim 2 , thienyl claim 2 , furanyl claim 2 , pyrrolyl claim 2 , pyrazolyl claim 2 , imidazolyl claim 2 , thiazolyl claim 2 , thiadiazolyl claim 2 , oxazolyl claim 2 , oxadiazolyl claim 2 , pyridyl claim 2 , pyrimidyl claim 2 , pyrazinyl claim 2 , pyridazinyl claim 2 , indolyl claim 2 , indazolyl claim 2 , benzimidazolyl claim 2 , benzoxazolyl claim 2 , benzodioxolyl claim 2 , benzothiazolyl claim 2 , benzothiadiazolyl claim 2 , benzothiophenyl claim 2 , dihydrobenzodioxinyl claim 2 , thienofuranyl claim 2 , thienothienyl claim 2 , thienopyrrolyl claim 2 , quinolinyl claim 2 , quinoxalinyl claim 2 , quinazolinyl claim 2 , cinnolinyl claim 2 , or triazolyl; and wherein each A is independently substituted with (R).57-. (canceled)8. The compound according to claim 4 , wherein each A is independently piperazinyl claim 4 , piperadinyl claim 4 , thienyl claim 4 , furanyl claim 4 , pyrrolyl claim 4 , pyrazolyl claim 4 , imidazolyl claim 4 , thiazolyl claim 4 , oxazolyl claim 4 , thiadiazolyl claim 4 , pyrrolidinyl claim 4 , pyridyl claim 4 , pyrimidinyl claim 4 , pyrazinyl claim 4 , pyridazinyl claim 4 , benzoxazolyl claim 4 , benzodioxolyl claim 4 , benzothiazolyl claim 4 , benzothiadiazolyl claim 4 , benzothiophenyl claim 4 , dihydrobenzodioxinyl claim 4 , thienofuranyl claim 4 , thienothienyl claim 4 , quinolinyl claim 4 , or triazolyl claim 4 , each of which is substituted with (R).910.-. (canceled)11. The compound according to claim 2 , wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (R).12. The compound ...

Antiviral compounds

The present invention relates to heterocyclic Compounds having antiviral activity. In particular, Compounds of formula (I):wherein B, W, X, Y, Q, R1, R2, R3, R4 and n are as defined herein, are useful in the therapy and prophylaxis of viral infection in mammals.

Macrocyclic anti-viral compounds

The present invention relates to heterocyclic compounds having antiviral activity. In particular, compounds of wherein B, W, X, Y, Z, R2, R3, R4, R5, T, T1, Q, Q1and n are as defined herein, and are useful in the therapy and prophylaxis of viral infection in mammals.

Antiviral compounds

The present invention relates to heterocyclic Compounds having antiviral activity. In particular, Compounds of formula (I): wherein B, W, X, Y, Q, R1, R2, R3, R4and n are as defined herein, are useful in the therapy and prophylaxis of viral infection in mammals.

Quinolizinones as integrin inhibitors

The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly alphaIIbbeta3 or alphav integrins such as alphavbeta3 and alphavbeta5. One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.

ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I 2. The compound according claim 1 , wherein{'sub': 1', 'p, 'each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzodioxine, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (R).'}35.-. (canceled)6. The compound according to claim 2 , wherein each A is independently piperazinyl claim 2 , piperadinyl claim 2 , thienyl claim 2 , furanyl claim 2 , pyrrolyl claim 2 , pyrazolyl claim 2 , imidazolyl claim 2 , thiazolyl claim 2 , oxazolyl claim 2 , thiadiazolyl claim 2 , pyrrolidinyl claim 2 , pyridyl claim 2 , pyrimidinyl claim 2 , pyrazinyl claim 2 , pyridazinyl claim 2 , benzoxazolyl claim 2 , benzodioxolyl claim 2 , benzothiazolyl claim 2 , benzothiadiazolyl claim 2 , dihydrobenzodioxinyl claim 2 , thienofuranyl claim 2 , thienothienyl claim 2 , quinolinyl claim 2 , or triazolyl.78.-. (canceled)9. The compound according to claim 1 , wherein B and B′ are independently absent claim 1 , Calkyl or Calkynyl.1011.-. (canceled)1318.-. (canceled)19. The compound according to claim 1 , wherein Ris halogen claim 1 , Calkyl which is unsubstituted or substituted one or more times by R claim 1 , —C(═O)OR claim 1 , —C(O)NRR claim 1 , hydroxyl claim 1 , cyano claim 1 , or Calkoxy.20. (canceled)21. The compound according to claim 1 , wherein R′ is methyl claim 1 , trifluoromethyl claim 1 , iodo claim 1 , CHOH claim 1 , or NHC(O)CH.22. The compound according to claim 21 , wherein u is 0.23. The compound according to claim 1 , wherein each Ris independently fluoro or methyl.24. The compound according to ...

Thiophene analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B, X, Y, R1, R1, R2, R2, R3, R3, R5, R5, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Antiviral compounds

The present invention relates to heterocyclic Compounds having antiviral activity. In particular, Compounds of formula (I):wherein B, W, X, Y, Q, R1, R2, R3, R4 and n are as defined herein, are useful in the therapy and prophylaxis of viral infection in mammals.

THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R 1 , X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R 2 , R 2 ', R 3 , R 3 ', R 4 , R 4 ', R 5 , R 5 'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Benzimidazole analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B′, X, Y, R 1 , R 1 ′, R 2 , R 2 ′, R 3 , R 3 ′, R 5 , R 5 ′, R 6 , m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R 1 , R 2 , R 2 ′, R 3 , R 3 ′, R 4 , R 4 ′, R 5 , R 5 ′, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Benzimidazole analogues for the treatment or prevention of flavivirus infections.

Los compuestos representados por la fórmula (I): (ver fórmula (I)) o sales y solvatos farmacéuticamente aceptables de los mismos, en donde A, B, B', X, Y, R1, R1', R2, R2', R3, R3', R5, R5´, R6, m, n o p son como se define en la presente, son útiles para el tratamiento de infecciones virales por flaviviridae.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I as described herein or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R 1 , R 2 , R 2 ', R 3 , R 3 ', R 4 , R 4 ', R 5 , R 5 ', m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R 2 , R 2 ', R 3 , R 3 ', R 4 , R 4 ', R 5 , R 5 'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Thiophene analogues for the treatment or prevention of flavivirus infections

The present invention relates to compounds represented by formula IA or pharmaceutically acceptable salts and solvates thereof which are useful for treating flaviviridae viral infections wherein R1 is C1-6 alkyl or C3-6 cycloalkyl; X is M is R5 is cyclohexyl which is unsubstituted or substituted one or more times by R13; R6 is or cyclohexyl which is substituted in the 4 position by R14; and Y, R14a and R14 are as defined herein.

Thiophene analogues for the treatment or prevention of Flavivirus infections

The present invention relates to compounds represented by formula IA or pharmaceutically acceptable salts and solvates thereof which are useful for treating flaviviridae viral infections wherein R 1 is C 1-6 alkyl or C 3-6 cycloalkyl; X is M is R 5 is cyclohexyl which is unsubstituted or substituted one or more times by R 13 ; R 6 is or cyclohexyl which is substituted in the 4 position by R 14 ; and Y, R 14a and R 14 are as defined herein.

Thiophene analogues for the treatment or prevention of Flavivirus infections

The present invention relates to compounds represented by formula IA or pharmaceutically acceptable salts and solvates thereof which are useful for treating flaviviridae viral infections wherein R 1 is C 1-6 alkyl or C 3-6 cycloalkyl; X is M is R 5 is cyclohexyl which is unsubstituted or substituted one or more times by R 13 ; R 6 is or cyclohexyl which is substituted in the 4 position by R 14 ; and Y, R 14a and R 14 are as defined herein.

Naphthyridine derivatives and their analogues inhibiting cytomegalovirus

The present invention relates to heterocyclic compounds, more particularly naphthyridine compounds having antiviral activity. In particular, compounds of formula (I) wherein B, W, X, Y, R 1 , R 2 , R 3 , R 4 , and n are as defined herein, are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.

Antiviral compounds

The present invention relates to heterocyclic Compounds having antiviral activity. In particular, Compounds of formula (I), wherein B, W, X, Y, Q, R1, R2, R3, R4 and n are as defined herein, are useful in the therapy and prophylaxis of viral infection in mammals.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I as described herein or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4, R4', R5, R5', m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Quinolizinones as integrin inhibitors

The present invention comprises novel compounds that are effective inhibitors of integrins, particularly αIIbβ3 or αv integrins such as αvβ3 and αvβ5. The present invention, according to one embodiment, comprises a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. Wherein R1, R2, R3 and R4 are as defined herein.

Naphthyridine derivatives and their analogues inhibiting cytomegalovirus

The present invention relates to heterocyclic compounds, more particularly naphthyridine compounds having antiviral activity. In particular, compounds of formula (I) wherein B, W, X, Y, R1, R2, R3, R4, and n are as defined herein, are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.

Thiophene analogues for the treatment or prevention of flavivirus infections

Naphthyridine derivatives and their analogues inhibiting cytomegalovirus

The present invention relates to heterocyclic compounds, more particularly naphthyridine compounds having antiviral activity. In particular, compounds of formula (I) wherein B, W, X, Y, R1, R2, R3, R4, and n are as defined herein, are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.

"method of inhibiting virus replication, compound, method of inhibiting cytomegalovirus replication, antiviral compound, use of a compound, pharmaceutical composition, pharmaceutical composition inhibiting virus and cytomegalovirus replication and antiviral pharmaceutical composition"

<B>"MéTODO DE INIBIçãO DA REPLICAçãO DE VìRUS, COMPOSTO, MéTODO DE INIBIçãO DA REPLICAçãO DE CITOMEGALOVìRUS, COMPOSTO ANTIVIRAL, UTILIZAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, COMPOSIçãO FARMACêUTICA INIBIDORA DA REPLICAçãO DE VìRUS E DE CITOMEGALOVìRUS E COMPOSIçãO FARMACêUTICA ANTIVIRAL" A presente invenção refere-se a Compostos heterocíclicos que possuem atividade antiviral. Especificamente, Compostos da fórmula (I) em que B, W, X, Y, Q, R~ 1~, R~ 2~, R~ 3~, R~ 4~ e n são conforme definido no presente, são úteis na terapia e profilaxia de infecções virais em mamíferos.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by Formula I: (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4, R4', R5, R5'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Quinolizinones as integrin inhibitors

Quinolizinones as integrin inhibitors

The present invention comprises novel compounds that are effective inhibitors of integrins, particularly αIIbβ3 or αv integrins such as αvβ3 and αvβ5. The present invention, according to one embodiment, comprises a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. Wherein R1, R2, R3 and R4 are as defined herein.

Thiophene analogues for the treatment or prevention of flavivirus infections

Macrocyclic anti-viral compounds

The present invention relates to heterocyclic compounds having antiviral activity. In particular, compounds of formula (I): wherein B, W, X, Y, Z, R2, R3, R4, R5, T, T?1, Q, Q1¿ and n are as defined herein, and are useful in the therapy and prophylaxis of viral infection in mammals.

Antivirale verbindungen

Naphthyridin-derivate mit cytomegalovirus inhibierender wirkung

Αναλογα θειοφαινιου για τη θεραπεια ή την προληψη λοιμωξεων που οφειλονται σε flavivirus

Η παρούσα εφεύρεση σχετίζεται με ενώσεις που αντιπροσωπεύονται από τον τύπο ΙΑ ή με φαρμακευτικώς αποδεκτά άλατα και διαλύματα αυτών, που είναι χρήσιμα για τη θεραπεία ιογενών λοιμώξεων που οφείλονται σε flaviviridae όπου το R1 είναι C1-6 αλκύλιο ή C3-6 κυκλοαλκύλιο. Το Χ είναι Μ είναι R5 είναι κυκλοεξύλιο που είναι μη υποκατεστημένο ή υποκατεστημένο μια ή περισσότερες φορές με R13. Το R6 είναι ή κυκλοεξύλιο που είναι υποκατεστημένο στη θέση 4 με R14 και τα Υ, R14a και R14 είναι όπως ορίζονται στο παρόν.